- Conditions
- Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
- Interventions
- TD-3504, 15N2-tofacitinib, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced May 21, 2026, 8:04 PM EDT